Stockscreener 앱 받기
6.816
4.54%
-0.324
전일 마감가:
$7.14
열려 있는:
$7.19
하루 거래량:
13,298
Relative Volume:
0.50
시가총액:
$12.92M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.79%
1개월 성능:
+36.59%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$6.60
$7.19
1주일 범위
$6.60
$7.28
52주 변동 폭
$2.90
$12.55
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
명칭
Neuphoria Therapeutics Inc
전화
781-439-5551
주소
100 SUMMIT DR, BURLINGTON
NEUP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
6.816 | 12.92M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | 재확인 | Maxim Group | Buy |
| 2022-01-10 | 개시 | Berenberg | Buy |
| 2022-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-01-10 | 개시 | Evercore ISI | Outperform |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
모두보기
Neuphoria Therapeutics Inc 주식(NEUP)의 최신 뉴스
Neuphoria to Present at the American Society of Clinical Psychop - GuruFocus
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting | NEUP Stock News - GuruFocus
Neuphoria Therapeutics to Present BNC210 Phase 2b Data at ASCP 2025 Annual Meeting - Nasdaq
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting - GlobeNewswire
Neuphoria Provides First Quarter 2025 Business Updates | NEUP St - GuruFocus
Neuphoria Therapeutics Inc. Reports Q1 2025 Progress and Upcoming Milestones for BNC210 and MK-1167 Programs - Nasdaq
Neuphoria Provides First Quarter 2025 Business Updates - GlobeNewswire
Neuphoria Therapeutics Says Cash Runway Extends Into Q3 2026SEC Filing - marketscreener.com
Neuphoria Therapeutics Inc. SEC 10-Q Report - TradingView
Neuphoria Therapeutics Delays 10-Q Filing - TipRanks
Neuphoria Therapeutics (NEUP) Outlines Robust 2025 Drug Developm - GuruFocus
Neuphoria Therapeutics IncMerck Pays $15M Milestone, Extends Cash Runway To Q3 2026 - marketscreener.com
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans - GlobeNewswire
Neuphoria receives $15M milestone payment from Merck - MSN
Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025 - GlobeNewswire
Neuphoria Therapeutics Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Neuphoria Therapeutics Inc Rings the Opening Bell - Nasdaq
Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes - MSN
Neuphoria Therapeutics’ Listing on Nasdaq - Global Legal Chronicle
Neuphoria Therapeutics Inc. (NEUP) reports earnings - Quartz
Neuphoria Therapeutics rises on $15 mln milestone payment from Merck - TradingView
Neuphoria Therapeutics shares surge on $15M Merck payment - MSN
Neuphoria To Receive $15 Mln Milestone Payment From Merck; Stock Up In Pre-market - Nasdaq
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - GlobeNewswire
Neuphoria Therapeutics to receive $15M milestone payment from Merck - MSN
Neuphoria Therapeutics shares surge on $15M Merck payment By Investing.com - Investing.com Australia
Here's Why Momentum in Neuphoria Therapeutics Inc. (NEUP) Should Keep going - MSN
Neuphoria Therapeutics Takes the Biotech Spotlight: U.S. Relocation and Nasdaq Debut Promise Game-Changing Opportunities - Jomfruland.net
Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Given New $21.00 Price Target at HC Wainwright - Armenian Reporter
Brokers Set Expectations for NEUP Q2 Earnings - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Stock - Defense World
FY2027 Earnings Estimate for NEUP Issued By HC Wainwright - Defense World
Why Neuphoria Therapeutics Inc. (NEUP) Surged on Friday - MSN
10 Firms Defy Market Pessimism - Insider Monkey
Stock market news: Nvni Group +254.36%, Allurion Technologies +153.92% among top gainers during mid day trading - Business Upturn
Stock market news: Neuphoria Therapeutics and Nvni Group saw surge of 134.96% and 245.64% concurrently during mid day trading - Business Upturn
Neuphoria Therapeutics regains Nasdaq compliance - Investing.com India
Neuphoria Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Australia
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder - Marketscreener.com
Neuphoria Therapeutics Inc (NEUP) 재무 분석
Neuphoria Therapeutics Inc (NEUP)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):